Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Lamivudine therapy in HBsAg-positive kidney allograft recipients

Preemptive lamivudine therapy, based on serial HBV DNA levels and clinical monitoring, improves the survival of HBsAg-positive renal allograft recipients, find researchers in the November issue of Hepatology.

News image

fiogf49gjkf04

Hepatitis B surface antigen (HBsAg)-positive kidney transplant recipients have increased liver-related mortality.

In this study, a research team from Hong Kong, China, examined the impact of lamivudine treatment on patient survival using a novel management protocol.

In addition, they examined the optimal time to start treatment, and the feasibility of discontinuing treatment.

They team measured serum hepatitis B virus (HBV) DNA levels serially in HBsAg-positive kidney transplant recipients.

Lamivudine was administered preemptively to patients with increasing HBV DNA levels, with or without elevation of aminotransferase levels.

The research team compared outcomes of patients who underwent transplantation before or after this preemptive management strategy.

During the study, 11 de novo patients and 15 existing patients received preemptive lamivudine therapy for 33 months.

The treatment criteria were met by de novo patients at 8 months after transplantation.

Suppression of HBV DNA and normalization of aminotransferase levels occurred in all treated patients.
Hepatology

The team identified suppression of HBV DNA and normalization of aminotransferase levels in all treated patients.

In addition, 21% had hepatitis B e antigen (HBeAg) seroconversion.

The team found that the survival of preemptively managed de novo transplant patients was similar to that of HBsAg-negative controls,

However, HBsAg-positive patients who underwent transplantation before institution of the preemptive management strategy, had inferior survival.

Lamivudine resistance developed in 40% of the patients.

The team attempted discontinuation of lamivudine in 12 low-risk patients after stabilization and was successful in 5.

Dr Tak Mao Chan's team concluded, "Preemptive lamivudine therapy based on serial HBV DNA levels and clinical monitoring improved the survival of HBsAg-positive renal allograft recipients".

"Treatment can be discontinued safely in selected patients after stabilization to minimize the selection of drug-resistant HBV mutants".

In a related editorial in the same publication, Dr Robert Perrillo, from Louisiana, USA, discusses the impact of HBV on progressive liver disease and survival after renal transplantation.

Dr Perrillo concludes, "Several questions remain unanswered with regard to the management of HBsAg-positive patients who undergo kidney transplantation".

"It is a reasonably safe bet, however, that the availability of a number of safe and effective medical treatments for chronic HBV infection will greatly diminish the potential impact that these questions have on management decisions in the future".

Hepatology 2002; 36: 1246-52
06 November 2002

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us